

Bleeding

- P-001 Molecular genetic investigations in Hereditary Hemorrhagic Telangiectasia in Hungary; identification of a founder mutation
Réka Gindele, Hungary
- P-002 Risk of minor and major bleeding in patients who switched from vitamin K antagonists to direct oral anticoagulants
Myrthe Toorop, The Netherlands
- P-003 Reversal of apixaban anticoagulation by andexanet alfa in healthy subjects: a subgroup analysis of the reversal activity using an optimized anti-FXa activity assay vs commercial anti-FXa assays
Genmin Lu, United States
- P-004 The influence of glomerular filtration rate on bleeding and mortality risk during hospitalization – multi center cohort
Sonja Salinger, Serbia
- P-005 DOAC Filter®: a useful tool to monitor unfractionated heparin anti-Xa activity after periprocedural interruption of anti-Xa direct oral anticoagulants
Nicolas Gendron, France
- P-006 Living Well with Haemophilia: The everyday experience of haemophilia in Europe in 2018
Camillo de Vivanco, Denmark
- P-007 The impact of specimen volume and haemolysis on routine coagulation test results: reducing the recollection burden in a high-throughput laboratory
Rebecca Toole, New Zealand
- P-008 A new fully automated FXIII activity assay.
Nikolaus Binder, Austria
- P-009 Dosage of factor IX in persons with Hemophilia B treated with recombinant FIX linked to an IgG Fc domain: Comparison of 3 methods in a French hospital
Andreas Perrier-Cornet, France
- P-010 Evaluation of a new extraction thromboplastin reagent with ISI close to 1.0 for the measurement of prothrombin time, international normalized ratio and factor assays.
Jonathan Douxfils, Belgium
- P-011 Importance of classification and genetic tests in the diagnosis and differential diagnosis of von Willebrand disease type 2N
Adrienne Kerényi, Hungary
- P-012 Developing an Assay for Anti-Emicizumab Antibodies in Patients with Haemophilia A
Tanya Fahmy, United Kingdom
- P-013 Evaluation of the analytical performances of new apixaban & rivaroxaban low range anti-FXa activity assays on STA-R & STA-Compact Max after reversal by andexanet alpha
Matthieu Bourdin, France
- P-014 Acquired FXIII deficiency due to anti-FXIII-A autoantibody; unusual laboratory and clinical characteristics
László Muszbek, Hungary

- P-015 Outcome of major haemorrhage in a tertiary cardiothoracic centre in patients with activated major haemorrhage protocol vs non-activated protocol.
Kathryn Chang, United Kingdom
- P-016 Gastrointestinal bleeding in patients with bleeding disorders
Bronwen Johns, United Kingdom
- P-017 Adaptation and comparison of the technical performance of two chromogenic FVIII assay reagents
Claire Flaujac, France
- P-018 Frequency of large deletions and duplications of F8 gene in hemophilia A patients from Serbia
Nina Ilic, Serbia
- P-019 Management of cardiovascular patients with hemorrhoidal bleeding under antiplatelet or anticoagulant therapy
Aleksandra Tsitskarava, Russia
- P-020 Chromogenic Factor VIII in Haemophilia A plasma of patients with emicizumab
Nikolaus Binder, Austria
- P-021 Case study: Laboratory experience of severe Haemophilia A inhibitor patients treated with Emicizumab
Jane Needham, United Kingdom
- P-022 Calibrated automated thrombogram values in pediatric craniosynostosis surgery
Saskia Luijnenburg, The Netherlands
- P-023 A multicenter experience with idarucizumab "in real world" as reversal anticoagulation of dabigatrá
Irene Amarilla Lanzas, Spain
- P-024 Correlation of the parameters of thromboelastogram with the results of coagulation tests in hemophilia A patients with prophylaxis
Valeriia Krasivska, Ukraine
- P-025 A new fully automated ADAMTS-13 activity assay.
Nikolaus Binder, Austria
- P-026 Investigating a potential new bleeding mechanism through novel, atypical GPIb-IX-V receptor complex mutants
Jack Yule, United Kingdom
- P-027 Rare bleeding disorders in southern Iran: revisited and updated data
Mehran Karimi, Iran
- P-028 Treatment with recombinant Von Willebrand factor (VWF) in type 2 Von Willebrand patient for a total knee replacement (TKR) and comparison with a precedent TKR with plasma-derived VWF concentrate
Claire Flaujac, France
- P-029 Unexplainable acute bleeding due to acquired factor XIII deficiency induced hyperfibrinolysis in patients with chronic phase of chronic myeloid leukaemia– three case reports
Bhaddika Jayaratne, Sri Lanka
- P-030 Inhibitor against coagulation Factor XIII: A case report
Mehran Karimi, Iran

- P-031 Systematic review of the risk of bleeding in patients with renal insufficiency treated with tinzaparin.
Esteve Colome, Spain
- P-032 Perioperative management of patients with rare bleeding disorders
Carlos Francisco Hernández Mata, Spain
- P-033 Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): rationale and design of a phase II double blind randomised controlled trial
Michael Desborough, United Kingdom
- P-034 Management of anticoagulant therapy in pacemaker implantation. retrospective study in an intensive care unit.
Pablo Romero García, Spain
- P-035 An unusual presentation of Clopidogrel side effects
Jurgita Janukonyte, Denmark
- P-037 Subgaleal hematoma in infant with severe hemophilia A
Ankica Jovanovic, Serbia
- P-038 Thrombosis in haemophilia – how could it happen?
Lucia Stanciakova, Slovakia
- P-039 Thrombotic complications and bleeding disorders of haemostasis
Lucia Stanciakova, Slovakia

Clotting

- P-040 The risk of a first venous thrombosis associated with elevated D-dimer and thrombin generation in elderly
Huijie Wang, The Netherlands
- P-041 Hypertension is associated with lower risk of venous thromboembolism in men
Magdalena Johansson, Sweden
- P-042 The association of a procoagulant state with venous thrombosis in patients with lower-leg injury
Carolina Touw, The Netherlands
- P-043 Is the Caprini score a useful tool to predict venous thrombosis in orthopedic patients?
Carolina Touw, The Netherlands
- P-044 Coagulation factor V is associated with immune response and tumor lymphocyte recruitment in breast cancer
Mari Tinholt, Norway
- P-046 Safety of rivaroxaban in the diagnostic work-up of deep vein thrombosis
Synne Fronas, Norway
- P-047 Tissue factor is constrained by interaction with the pdz-1 domain of magi-1 protein
Mohammad Mohammad, United Kingdom
- P-048 Kidney injury can be a predictor of intrahospital mortality and fatal bleeding in patients with acute pulmonary embolism
Boris Dzudovic, Serbia

- P-049 Plasma levels of leptin and future risk of incident venous thromboembolism
Vania Morelli, Norway
- P-050 Pregnancy-related venous thromboembolism risk in women from families with thrombophilia: results from the MARseilles FAMily Study on venous Thrombosis (MARFAST)
Pierre Suchon, France
- P-051 Transfusion requirements in adult patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibitors receiving ravulizumab and eculizumab: results from a phase 3 non-inferiority study
Talha Munir, United States
- P-052 Prevalence and incidence of venous thromboembolism in Norway 2010 – 2017
Waleed Ghanima, United Kingdom
- P-053 Efficacy and safety of the long-acting complement C5 inhibitor ravulizumab in adult patients with atypical haemolytic uraemic syndrome (aHUS)
Marie Scully, United Kingdom
- P-054 Hidden antithrombin variant detected by whole genome sequencing that modulates the N-glycosylation efficacy. Clinical implications and basic mechanisms.
María Eugenia De La Morena-Barrio, Spain
- P-055 Recurrence risk of transient inflammation-associated venous thromboembolism: similar to provoked, unprovoked or in-between?
Soerajja Bhoelan, The Netherlands
- P-056 Patients with high post-endovascular treatment plasma levels of neutrophil activation markers are at higher risk of poor functional outcome, HT, and mortality.
Lucas Di Meglio, France
- P-057 Plasma levels of complement component C5 are associated with future risk of incident venous thromboembolism
Espen Waage Skjeflo, Norway
- P-058 Detection of pulmonary embolism in exhaled breath condensate - a porcine model
Inger Lise Gade, Denmark
- P-059 The pharmacokinetics and pharmacodynamics of nadroparin in children with venous thromboembolism
Marit Boerma, The Netherlands
- P-060 Comparison of coagulation properties of microparticles derived from platelets, erythrocytes, leukocytes and endothelial cells
Alexey Mazurov, Russia
- P-061 Inhibitor effects on clot growth: different profiles of inhibition.
Cornelis Klufft, The Netherlands
- P-062 Alpha2-plasmin inhibitor and its C-terminal proteolytic variation in venous thrombosis
Éva Katona, Hungary
- P-063 Rosuvastatin use reduces the procoagulant phospholipid (PPL) activity in patients with venous thromboembolism: a randomized controlled trial
John-Bjarne Hansen, Norway
- P-064 Replacement of pt-inr monitoring of warfarin with fiix-nr reduces thromboembolism, anticoagulation variability, testing frequency and dose adjustment need without raising time in

range.

Alma Oskarsdottir, Iceland

- P-065 The Value of Neuroimaging and Implications for Long-term Neurological Sequelae of Thrombotic Thrombocytopenic Purpura: A Tertiary Centre Experience
Rebecca Jane Shaw, United Kingdom
- P-066 Limitations of the Villalta scale in diagnosing the post-thrombotic syndrome
Marit Engeseth, Norway
- P-067 Characterisation of a novel genetically modified fxiii-a I34v model shows altered thromboembolism dynamics
Adomas Baranauskas, United Kingdom
- P-068 The risk of deep vein thrombosis and pulmonary embolism attributed to recognized prothrombotic genotypes
Sigrid Brækkan, Norway
- P-069 Anticoagulant treatment duration and risk of recurrent venous thromboembolism: an instrumental variable analysis from the MEGA follow-up study
Fleur van Velthoven, The Netherlands
- P-070 Unravelling the molecular mechanism of tick protein BSAP1, a putative extrinsic coagulation pathway inhibitor
Stepan Denisov, The Netherlands
- P-072 Additive effect of oxygen saturation and chronic obstructive pulmonary disease on the risk of incident venous thromboembolism
John-Bjarne Hansen, Norway
- P-073 The LumiraDx Platform INR test: Performance and ease of use in an anticoagulation clinic setting
Jayne Ellis, United Kingdom
- P-074 Thrombin generation in patients with lower-leg injury
Carolina Touw, The Netherlands
- P-075 Identification of a circulating lipid profile associated with venous thromboembolism
Álvaro Fernández-Pardo, Spain
- P-076 The role of bacterial proteases in prothrombin activation
Vincenzo De Filippis, Italy
- P-077 Role of factor VIII and von Willebrand factor in the relation between risk of venous thrombosis and their risk factors
Filippo Castelli, Italy
- P-079 MicroRNA-494 upregulates TFPI-2 expression in MCF-7 breast cancer cells
Marianne Andresen, Norway
- P-080 Hospital-based Diagnoses of Low Back Pain and Risk of Myocardial Infarction, Stroke, and Venous Thromboembolism
Emil Zål Riahi, Denmark
- P-081 Dabigatran Therapy Provides Better Inhibition Against Intracardiac Activation of Hemostasis as Compared to Vitamin K Antagonists During Cryoballoon Catheter Ablation of Atrial Fibrillation
Zsuzsa Bagoly, Hungary

- P-082 Early mortality risk is associated with prolonged clot lysis time in acute pulmonary embolism: contribution of NETosis
Michał Ząbczyk, Poland
- P-083 In-depth epitope mapping of anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura patients using a large library of ADAMTS13 fragments
Kadri Kangro, Belgium
- P-084 High plasma levels of mannose-binding lectin are associated with non-O blood type and increased risk of venous thromboembolism
Robin Amanda Liang, Norway
- P-085 Exploring a novel interaction between the intrinsic pathway of coagulation and complement
Samantha Heal, United Kingdom
- P-086 Plasmatic protein C levels are determined by genetic variants in the promoter and the intron 2 of the protein C gene
Álvaro Fernández-Pardo, Spain
- P-087 Plasma P-selectin as Predictive Biomarker for Incident Venous Thromboembolism in Women
Tine Hiorth Schøyen, Norway
- P-089 Decadal results from a single centre cohort: Maternal and fetal outcomes in women with antiphospholipid antibodies
Karen Schreiber, United Kingdom
- P-090 Novel thermostable inhibitor of contact activation TICA effectively blocks contact activation in low tissue factor thrombin generation.
Tom van de Berg, The Netherlands
- P-091 Does a meal affect thrombin generation? New insights from the NEO study
Sara Arcudi, Italy
- P-092 Neutrophil Extracellular Traps Accelerate Clotting and Produce a Denser Clot Structure in Plasma
Yu Shi, United Kingdom
- P-093 Impaired right ventricular function in patients with chronic thromboembolic disease
Øyvind Jervan, Norway
- P-094 The ratio of factor VIIa:tissue factor content within microvesicles determines the differential influence on endothelial cells.
Yahya Madkhali, United Kingdom
- P-095 Pregnancy outcomes in patients with atypical haemolytic uraemic syndrome
Marie Scully, United Kingdom
- P-096 Characterisation of a novel F5 gene mutation (Ala2086Asp, Factor V Besançon) associated with factor V deficiency and recurrent venous thrombosis
Elisabetta Castoldi, The Netherlands
- P-097 Design of a "catch and release assay" for circulating FXIa.
Stan van der Beelen, The Netherlands
- P-098 Opium as a risk factor for coronary artery disease in young Iranians: results from the premature CAD Milano-Iran (MIran) study
Alberto Maino, Italy

- P-099 A validated metabolomic plasma profile associated with venous thromboembolism
Álvaro Fernández-Pardo, Spain
- P-101 The impact of age on the pharmacological activity of factor X inhibitors, rivaroxaban and apixaban
Emmanouela Kampouraki, United Kingdom
- P-102 The effects of a peripheral venous catheter compared to repeated venepunctures on markers of coagulation, inflammation, and endothelial function
Line Espenhain, Denmark
- P-103 Discrepant interpretation of HIT screening results on the same sample - data from a UK NEQAS for Blood Coagulation exercise.
Anna Lowe, United Kingdom
- P-104 Molecular genetic investigations in antithrombin deficient children; investigation of genotype-phenotype relationship
Zsuzsanna Bereczky, Hungary
- P-105 New fibrinolytic technology based on serine protease subtilisin
Eugene Roitman, Russia
- P-106 The association of antithrombin activity with the risk assessment of acute pulmonary embolism and predictive significance for 30-day mortality
Boris Dzudovic, Serbia
- P-107 Plasma clot formation, lysis, fibrin fiber density and mechanics from patients with acute PE before and after initial treatment with low molecular weight heparin
Stephen Baker, United Kingdom
- P-109 Examination of the interacting domains between the extracellular domains of tissue factor and β 1-integrin and their influence on cell proliferation.
Sophie Featherby, United Kingdom
- P-111 Soluble fibroblast activation protein (sFAP) and alpha2-plasmin inhibitor p.Arg67Trp polymorphism in venous thrombosis
Barbara Baráth, Hungary
- P-112 Analysis of the differential expression of miRNAs present in plasma and contained within microparticles in severe forms of pulmonary hypertension
Julia Oto, Spain
- P-113 The effects of acute and chronic exercise on Factor VIII and von Willebrand antigen plasma levels in well trained athletes
Nikolaos Androulakis, Greece
- P-114 Empowering cancer patients for non-pharmacological primary prevention and early recognition of cancer-associated venous thromboembolism (VTE): the EMPATIC-CP survey.
Carme Font Puig, Spain
- P-115 The glycan structure of factor XIII B subunit
Boglárka Hurják, Hungary
- P-116 Dietary zinc modulates several haemostatic parameters
Um-May Sumya, United Kingdom
- P-117 A phase 3 study of ravulizumab (ALXN1210) vs eculizumab in adults with paroxysmal nocturnal hemoglobinuria currently treated with eculizumab: subgroup analyses by transfusion history

and demographics
Austin Kulasekararaj, United States

- P-118 Prediction and measurement of human PEG plasma levels after administration of PEGylated biologics and their value for safety assessment
Andreas Baumann, Germany
- P-119 Global hemostatic assays (OHP and ETP) have no additional value compared to D-dimer in the diagnosis of acute venous thrombosis
Maria Farm, Sweden
- P-120 Obtaining renal function results before empiric rivaroxaban in the diagnostic work-up of deep vein thrombosis
Synne Fronas, Norway
- P-121 The effect of DOAC-Remove on activated protein C resistance testing in venous thromboembolism patients receiving direct oral anticoagulants
Magdalena Kopytek, Poland
- P-122 Clinical outcomes of International Normalized Ratios Measured every 8 Weeks versus 12 Weeks in Venous Thromboembolism Patients with Stable Warfarin Dose: Prospective Cohort study
Fahad Aleidan, Saudi Arabia
- P-123 Plasma lipopolysaccharide-binding protein is a biomarker for future deep vein thrombosis in women; results from untargeted discovery and validation studies
Søren Beck Jensen, Norway
- P-124 Antiphospholipid antibodies and thrombosis in non BCR-ABL myeloproliferative neoplasms
Ruta Dambrauskiene, Lithuania
- P-125 Why do we not investigate suspected deep vein thrombosis according to current guidelines?
Johan Tjällman, Sweden
- P-126 An unusual case of abdominal pain
Eleonora Rizzi, Italy
- P-127 The effects of Edoxaban on routine coagulation tests
Hazel Medforth, United Kingdom
- P-129 The role of red blood cells surface proteins in hemostasis and thrombosis
Karina Vidovic, Sweden
- P-130 The FibWave: a new rapid and relevant tool for the evaluation of anticoagulant drugs
Jonathan Evrard, Belgium
- P-131 Incidence of prothrombotic risk factors in perinatal stroke onset
Jelena Vukajlovic, Serbia
- P-132 Evaluation of the new QXpert Hemostasis Analyzer for routine coagulation tests
Pierre Toulon, France
- P-133 Course of fatigue symptoms following initiation of rivaroxaban for the treatment of venous thromboembolism
Waleed Ghanima, Norway
- P-134 Impact of duration of anticoagulant therapy on survival and bleeding or thrombotic complications in patients with cancer-associated thrombosis: data from a retrospective cohort

study.

Annalisa Dalla Salda, Italy

- P-135 Validation of a model with coagulation-related markers for the diagnosis of periprosthetic joint infection
Julia Oto, Spain
- P-136 The therapeutic plasma exchange (TPE) in patients with thrombotic thrombocytopenic purpura (TTP)
Bratislav Stankovic, Serbia
- P-137 D-dimer as a stand-alone test to rule out deep vein thrombosis
Fridtjof Rinde, Norway
- P-138 Less is more: Reduced anticoagulation therapy in patients after mechanical aortic On-X valve replacement in real life. Experience of a Spanish single centre.
Jose Agustín Rodríguez-Alén, Spain
- P-139 Plasma level of complement factor B is associated with risk of future venous thromboembolism
Søren Beck Jensen, Norway
- P-140 Plasma Von Willebrand Factor (VWF) and ADAMTS13 profiles in patients with Antiphospholipid syndrome (APS) and Systemic lupus erythematosus (SLE)
My Nhi Dang, United Kingdom
- P-141 Even if new scores enhance D-dimer testing relevance, D-dimer testing will still be limited if not combined with an appropriate clinical score
Poenou Geraldine, France
- P-142 Plasma circulating free DNA levels and DNase I activity are associated to an increased risk of venous thromboembolism
Julia Oto, Spain
- P-143 Profile of thrombin generation in children using low tissue factor picomolar concentration with and without thrombomodulin
Susanna Gassiot, Spain
- P-144 Current approach to antithrombotic therapy in patient with acute myocardial infarction in pregnancy
Nebojsa Antonijevic, Serbia
- P-145 The role of thrombotic risk factors in the aspect of pregnant women anemia correction
Lidiya Buzyan, Russia
- P-146 The mechanism of coagulating action of positively charged polyamidoamine dendrimers of low generation
Liliya Mukhametova, Russia
- P-147 Lot Specific differences in POC INR testing: UK NEQAS BC investigation
Dianne Kitchen, United Kingdom
- P-148 Altered coagulation status in the pathogenesis of Buruli ulcer
Louise Tzung-Harn Hsieh, United Kingdom
- P-149 Cerebral Venous Sinus Thrombosis as First Manifestation of Behçet' s Disease
Maria Mylona, Greece

- P-150 patient preferences for the treatment of paroxysmal nocturnal hemoglobinuria: results of a patient survey of ravulizumab (ALXN1210) and eculizumab in the UK
Ioannis Tomazos, United States
- P-151 Patient's preferences for decision-making in anticoagulation: Beyond the clinical criteria
Olga Gavín, Spain
- P-152 Evaluation of the challenges in the diagnostic methods for the detection of lupus anticoagulant in a third level hospital.
Sergio Pinzón, Spain
- P-153 Recurrence of VTE in the long-term period: a perspective study
Giacomo Turatti, Italy
- P-155 Argatroban for therapeutic anticoagulation in two patients with acute thrombosis and heparin resistance
Irina Mindlina, United Kingdom
- P-156 Reference intervals of routine coagulation tests in healthy term-pregnant Greek women
Eleni Vagdatli, Greece
- P-157 Evaluation of EQA material on Yumizen G 200 – coagulation analyser: UK NEQAS for Blood Coagulation study.
Liia Brown, United Kingdom
- P-158 Fibrinogen structure and function under oxidative stress condition
Jana Stikarova, Czech Republic
- P-159 In vitro determination of the amount of in vivo formed active thrombin in cohorts of patients with various diagnosis
Jan Dyr, Czech Republic
- P-160 Plasma fractionation: conventional and chromatographic method for factor VIII purification
Natalia Shurko, Ukraine
- P-161 A case of slow resolution upper extremity DVT
Alice Pirovano, Italy
- P-162 Management of the repeated thrombotic complications and antithrombin deficiency
Lucia Stanciakova, Slovakia
- P-163 Risky pregnancy and anticoagulant prophylaxis of the thromboembolic events
Lucia Stanciakova, Slovakia
- P-164 Is CHA₂DS₂-VASc Score Useful in Patients with Low Thromboembolic Risk? A Case Report.
Veronica Vassia, Italy
- P-165 Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics
Naser Shagerdi Esmaeli, Iran
- P-166 cavernous sinus thrombosis in AML m3 case under treatment with ATRA
Mehrdad Payandeh, Iran

Platelets

- P-167 Contribution of the mRNA binding protein CPEB4 in platelet biology through translational control.
Pablo García De Frutos, Spain
- P-168 Exposure of platelet-derived FXIII-A on the activated membrane is dependent on $\alpha\text{IIb}\beta_3$ and intracellular signalling via caspases and Src family kinases
Fahad Alshehri, United Kingdom
- P-169 Dimeric GPVI interacts with the D/aC-region of fibrinogen
Rui-Gang Xu, United Kingdom
- P-170 Platelet sialylation as a new biomarker of immature platelets
Alexandre Kauskot, France
- P-171 Platelet PN-1 regulates clot structure and retraction
Stephane Loyau, France
- P-172 Study of Aspirin and Clopidogrel Resistance by Light Transmittance Aggregometry and Its Association with Adverse Outcomes in Indian Stable Coronary Artery Disease Patients
Nirmal Ghati, India
- P-173 Disagregin: a possible new $\alpha\text{IIb}\beta_3$ integrin inhibitor to prevent arterial thrombosis
Danique van den Kerkhof, The Netherlands
- P-174 Coagulation factor XIII in platelet microparticles formed by receptor mediated and non-receptor mediated platelet activation
Laura Somodi, Hungary
- P-175 Non-psychoactive phytocannabinoids inhibit platelet activation and thrombus formation
Eman Alzahrani, United Kingdom
- P-176 Dasatinib attenuates thrombin generation and clot retraction of convulxin activated human platelets
Ildikó Beke Debreceni, Hungary
- P-177 A shear flow-based assay to assess rituximab prophylaxis in acquired Thrombotic Thrombocytopenic Purpura
Marie Scully, United Kingdom
- P-178 IV abciximab used as a rescue therapy for instant reocclusions during endovascular therapy for acute ischemic stroke
Jean-Philippe Desilles, France
- P-179 Intracellular zinc stimulates reactive oxygen species generation and modifies antioxidant system in platelets
Maria Lopes-Pires, United Kingdom
- P-180 Correlation of Glycated Hemoglobin with Platelet Indices
Eleni Vagdatli, Greece
- P-181 Predictors of contrast-induced nephropathy in patients with ACS after percutaneous coronary intervention
Aisulu Zhunuspekova, Kazakhstan

- P-182 Developing mouse models to investigate the mechanism of SLFN14 mutations in inherited thrombocytopenia
Rachel Stapley, United Kingdom
- P-183 Response to antiplatelet therapy measured by multiplate impedance aggregometry and bleeding complications in bypass cardiac surgery patients
Tina Novakovic, Serbia
- P-184 The features of acquired thrombotic thrombocytopenic purpura occurring at advanced age
Pasquale Agosti, Italy
- P-185 Effect of Thrombopoietin Receptor Agonists (TPO-RAs) on Neutrophil Extracellular Trap (NET) Formation in Immune Thrombocytopenia (ITP)
Lamyra Garaebti, Norway
- P-186 Influence of the P2Y12 receptor inhibitor action in patients with coronary heart disease after implantation of DES stents in view of CYP2C19 gene polymorphisms
Jamol Uzokov, Uzbekistan
- P-187 Platelets in the uremic milieu: Exploring the link between protein carbamylation and platelet dysfunction in ESRD
Veronika Binder, Norway
- P-188 Adenosine receptor agonists exhibit antiplatelet effect and ability to overcome P2Y12 receptor antagonists drug resistance
Nina Wolska, Poland
- P-189 Statins potentiate the antibacterial effect of platelets on Staphylococcus aureus
Laurence Camoin-Jau, France
- P-190 Retrospective study on the management of antiplatelet therapy in pacemaker implantation in an intensive care unit
Pablo Romero Garcia, Spain
- P-191 Predictive factors for successful splenectomy in children with chronic immune thrombocytopenic purpura - single center experience
Milena Jovic, Serbia
- P-192 Effect of eucalyptol (1,8 cineole) on the modulation of platelet function, thrombosis, haemostasis and platelet-mediated inflammation
Kahdr Alatawi, United Kingdom
- P-193 Evaluation of DOAC Filter® to neutralize argatroban induced interferences on routine coagulation tests.
Nicolas Gendron, France
- P-194 Comparison of platelet functional activity in children and adults
Evgeniya Ponomarenko, Russia
- P-195 The prognostic value of CYP2C19 gene polymorphisms in the development of adverse cardiovascular events
Aisulu Zhunuspekova, Kazakhstan
- P-196 Novel continuous flow cytometry approach to ITP diagnosis is capable of identifying subtypes of the disease and moving forward its understanding
Maria Sorokina, Russia

- P-197 Diagnostic and therapeutic dilemmas in HELLP syndrome
Andreas Perrier-Cornet, France
- P-198 Mathematical model of platelet response to collagen-related peptide activation suggests a role for PNX-1 in GPVI-induced platelet activation.
Maria Stepanyan, Russia
- P-199 Implementability of automated platelet aggregometry on coagulation analyzers for pediatric population
Susanna Gassiot, Spain
- P-200 Strong platelet activation in response to ADP in large platelet aggregates
Andrei Kumar Garzon Dasgupta, Russia
- P-201 Correlation of spontaneous platelet aggregation with stent length in patients undergoing percutaneous coronary intervention
Nikolaos Androulakis, Greece
- P-202 A role for vitamin D in inter-individual variation in platelet function
Ebtihal Alfatani, Ireland
- P-203 Flow cytometry for platelet functional characterization in children with essential thrombocythemia
Dmitrii Polokhov, Russia
- P-204 Sticky platelet syndrome in patients with thromboembolic complications
Lucia Stanciakova, Slovakia
- P-205 How could pregnancy in women with sticky platelet syndrome be managed?
Lucia Stanciakova, Slovakia
- P-206 Long lasting prothrombotic state implied by changes of plasma von Willebrand factor parameters (antigen level, collagen binding activity and multimerisation) after radical prostatectomy
Jolan Harsfalvi, Hungary
- P-207 PKC-delta-dependent pathways contribute to the exacerbation of the platelet activity in Crohn's disease
Younes Zaïd, Morocco
- P-208 Filipino cultural beliefs: an input to genetic counselling
Jayrelle Safran, Philippines

Vessel Wall

- P-209 Thrombomodulin-bound thrombin induces inflammatory signaling through direct cleavage and activation of protease-activated receptor 2
Dorothea Heuberger, Switzerland
- P-210 Endothelial-to-mesenchymal transition in venous thrombosis
Sara Robin, France
- P-211 Interaction of coagulation factor XII with the opportunistic pathogen *Candida albicans*
Maria-Louise Williams, United Kingdom
- P-212 Investigating the role of neutrophils and NETs in *Staphylococcus aureus* endocarditis
Severien Meyers, Belgium

- P-213 Development of novel imaging tracers of microcalcification for early detection of vulnerable atherosclerotic plaques
Anouk Gentier, Belgium
- P-214 Extracellular vesicles from patients with pulmonary arterial hypertension modulate endothelial function and angiogenesis
Avinash Khandagale, Sweden
- P-215 Acute hemorrhagic edema of infancy – is that really a mild, benign disease?
Rasa Medovic, Serbia
- P-216 The antiangiogenic effects of acetylsalicylic acid in patients with polycythemia vera
Eugene Roitman, Russia
- P-217 Endothelial Damage and Hypercoagulable State in Diabetic Patients with Gangrene Diabeticum
Sry Suryani Widjaja, Indonesia